Memo Therapeutics said that a Swiss funding program for COVID-19 medicines has granted the company CHF 10.5 million for clinical development of the company's COVAB 36 inhaled fully-human monoclonal antibody for the treatment of SARS-CoV-2 infection, and the Swiss government will have the option to purchase doses of the antibody following approval. Memo said that the … [Read more...] about Memo Therapeutics gets funding from Swiss government for development of inhaled mAb for COVID-19
Business
IDRI gets BARDA contract for intranasal RNA flu vaccine
US-based non-profit biotech Infectious Disease Research Institute (IDRI) said that it has received a 2-year contract from the Biomedical Advanced Research and Development Authority (BARDA) for development of an intranasal RNA vaccine against influenza as part of BARDA's "Beyond the Needle" initiative. The initial vaccine will be targeted against H5N1 flu. IDRI … [Read more...] about IDRI gets BARDA contract for intranasal RNA flu vaccine
Aerogen to supply nebulizers for delivery of CanSinoBio’s Convidecia inhaled COVID-19 vaccine
Nebulizer maker Aerogen and CanSino Biologics have signed a development and commercial supply deal for the use of Aerogen's vibrating mesh nebulizer technology for delivery of CanSinoBIO’s Convidecia inhaled vaccine against COVID-19. Terms of the deal were not disclosed. Earlier this year, CanSinoBio announced positive results from a Phase 1 trial of the Ad5-nCoV … [Read more...] about Aerogen to supply nebulizers for delivery of CanSinoBio’s Convidecia inhaled COVID-19 vaccine
Aerami Therapeutics to go public through SPAC merger
Inhaled drug developer Aerami Therapeutics has announced that it will go public through a merger with a special purpose acquisition company (SPAC) called FoxWayne Enterprises Acquisition Corp., and the resulting company’s common stock will be listed on the Nasdaq Capital Market. According to Aerami, the proceeds from the merger will be used for further development of … [Read more...] about Aerami Therapeutics to go public through SPAC merger
CF Foundation providing $3.5 million for development of Pulmocide’s inhaled opelconazole
The Cystic Fibrosis Foundation announced that it is providing $3.5 million for a Phase 2 study of Pulmocide Ltd's PC945 inhaled opelconazole for the prevention of pulmonary Aspergillus infections following lung transplantation. The CF Foundation noted that this is the organization's first investment in development of a drug specifically for treatment related to lung … [Read more...] about CF Foundation providing $3.5 million for development of Pulmocide’s inhaled opelconazole
Lupin acquires rights to TTP’s SMI technology
Lupin announced that it has acquired exclusive global rights to soft mist inhalation technology developed by Cambridge, UK design company TTP, and the two companies will co-develop the SMI device for delivery of inhaled drugs. Formulation development, regulatory submissions, commercial manufacturing, and commercialization of soft mist inhalers based on the TTP … [Read more...] about Lupin acquires rights to TTP’s SMI technology
Pharmascience to discontinue pms-sodium cromoglycate inhalation solution
Canadian pharma company Pharmascience has announced that it will stop manufacturing pms-sodium cromoglycate inhalation solution due to a 95% drop in demand over the past 15 years. Pharmascience now says it will sell pms-sodium cromoglycate for $24.23 per 50-nebule unit until it runs out of inventory. According to a November 19, 2021 Canadian news report, the … [Read more...] about Pharmascience to discontinue pms-sodium cromoglycate inhalation solution
Janssen launches Spravato nasal spray in Australia
Janssen Pharmaceutical announced that it has launched Spravato esketamine nasal spray in Australia for the treatment of treatment-resistant depression following approval by the TGA. The company also said that will file a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) for listing on the Pharmaceutical Benefits Scheme (PBS). Spravato is now … [Read more...] about Janssen launches Spravato nasal spray in Australia
Padagis launches generic version of Zomig nasal spray
Padagis (formerly Perrigo's generic prescription pharmaceutical business) has announced the launch of its generic version of Zomig zolmitriptan nasal spray for the treatment of migraine headaches in patients aged 12 and older. Altaris acquired Padagis from Perrigo in July 2021, and the FDA approved Padagis' ANDA for the unit dose nasal spray on September 30, 2021. … [Read more...] about Padagis launches generic version of Zomig nasal spray
Birmingham Biotech licenses antiviral nasal spray from the University of Birmingham
Birmingham Biotech said that it has licensed a carrageenan/gellan antiviral nasal spray from the University of Birmingham and intends to market the spray in the UK and in Asian countries for protection against COVID-19 starting in early 2022. The license excludes marketing rights in India but includes the rest of the world. Birmingham Biotech currently sells … [Read more...] about Birmingham Biotech licenses antiviral nasal spray from the University of Birmingham